-
Innovent and Eli Lilly will jointly announce final clinical results and biomarker analysis of the Phase Ib study of Dabosu (sintilimab injection) combined with bevacizumab in the treatment of advanced hepatocellular carcinoma at ASCO GI in 2022 result
Time of Update: 2022-02-18
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prne
-
The latest research: China's original targeted drug may be a new solution for the treatment of brain metastases from breast cancer
Time of Update: 2022-02-17
" Yan Min introduced that according to the research results, for HER2-positive breast cancer brain metastases, pyrotinib combined with capecitabine can effectively control both intracranial and extracranial lesions .
-
Innovative drug for chronic cough: the world's first selective P2X3 receptor antagonist significantly reduces cough frequency!
Time of Update: 2022-02-17
Lyfnua is an oral, selective P2X3 receptor antagonist indicated for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults .
At 24 weeks, cough-related quality of life was significantly improved in the 45 mg twice-daily dose group compared with placebo (HR=1.
-
PacBio and CARE4REVER Collaborate on Rare Disease Research
Time of Update: 2022-01-27
05, 2022 (GLOBE NEWSWIRE) -- PacBio, a leading provider of high-quality long-sequence sequencing platforms, announced today that they will be collaborating on some of Canada's most complex cases of unexplained rare diseases .
-
Can Omicron escape the new crown test?
Time of Update: 2022-01-27
The latest scientific gossip list is released: eating shrimp and fruit together will produce arsenic, myopia will not get presbyopia also-- Can Omicron escape the new crown test?
-
The new version of the National Medical Insurance List is officially implemented, and the once-a-week hypoglycemic drug Novotel benefits diabetic patients
Time of Update: 2022-01-26
In the field of diabetes treatment, Novotel® (Semaglutide Injection), a new hypoglycemic drug , was included in the national medical insurance list reimbursement system within 4 months of its listing due to its significant clinical benefits, which will further improve this product.
-
Xinruinuo Announces Appointment of Mr. Huang Haoyu as Chief Executive Officer
Time of Update: 2022-01-26
Its English name "SanReno" represents the concept of "three companies working together to focus on nephrology-related diseases " , and the Chinese name "Xinrui Nuo " is taken from the original intention of "keeping the promise of creating a healthy and auspicious life for patients and society" .
-
Yikun Bio completed $100 million in Series B financing, led by Sequoia China and Morningside Ventures
Time of Update: 2022-01-26
Relying on its Suzhou industrialization base and Singapore R&D base, Yikun Bio has accelerated its layout in the global industrial chain in the past two years, expanded the domestic market with innovative technology platforms such as advanced clinical mass spectrometry, panoramic pathology, and molecular diagnosis, and adopted cooperative research and development, investment and mergers and acquisitions.
-
Brooks' Axonda acquires PacBio's HiFi sequencing system again
Time of Update: 2022-01-26
Ginger Zhou, vice president and general manager of Azenta Life Sciences, said: "We are excited to provide a best-in-class long-read sequencing platform to support customers with our unique solutions that significantly enhance our capabilities .
-
Yuyue Medical won the National Intelligent Manufacturing Pilot Demonstration Factory in 2021
Time of Update: 2022-01-26
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
-
Gather to win!
Time of Update: 2022-01-26
Yuyue Medical has participated in a number of academic conferences, and released the first "Expert Consensus on Clinical Application of Emergency Adult Transnasal High Flow Oxygen Therapy" in the emergency department with dozens of experts, leading the industry to promote the popularization of cutting-edge solutions .
-
Ruiyang Pharmaceutical's first review of 1 billion varieties
Time of Update: 2022-01-26
On January 5, the official website of the State Food and Drug Administration showed that Ruiyang Pharmaceutical's 3 types of generic drugs, Roxatidine Hydrochloride Acetate for Injection, were approved for production and deemed to have been reviewed.
-
China National Medical Products Administration Approves Baizean(R) for Second-Line or Third-Line Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Time of Update: 2022-01-26
The company announced today that the China National Medical Products Administration (NMPA) has approved BeiGene's anti-PD-1 antibody drug Baizean® ( tislelizumab injection) for locally advanced or metastatic non-small cell lung cancer Second- or third-line therapy for patients with NSCLC .
-
Inspur Information accelerates the development of smart medical care based on the "storage as a platform" strategy
Time of Update: 2022-01-25
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
For example, in the medical industry, by storing, mining, and analyzing data to release its value, it can improve the medical experience, the efficiency and quality of diagnosis and treatment, the level of operation management and innovation, and help the digital transformation of medical care to develop better .
-
Jiutian Bio and China Eye Valley signed a memorandum of strategic cooperation to promote the development of ophthalmic gene therapy
Time of Update: 2022-01-25
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
This time, China Eye Valley and Jiutian Bio have signed a memorandum of strategic cooperation, and will work together to promote the innovative development of global advanced gene therapy in domestic ophthalmology and contribute to the benefit of ophthalmic patients .
-
Fosun Pharma and Insilicon Announce Strategic Cooperation
Time of Update: 2022-01-25
"This collaboration aims to combine Insilico's end-to-end AI-driven drug discovery platform with Fosun Pharma's strong clinical development and commercial promotion capabilities to discover and develop a combination of innovative drugs and therapies .
-
Junshi Biotech and Coherus expand cooperation in the field of tumor immunity and will jointly develop and commercialize JS006 (anti-TIGIT monoclonal antibody) in the United States and Canada
Time of Update: 2022-01-25
62em; font-family:"Arial"; color:black; margin:0in; } </> Junshi Biosciences and Coherus plan to conduct clinical studies on multiple tumor types to evaluate the combination therapy of toripalimab and JS006 Combination therapy of PD-1 and TIGIT inhibitors is expected to expand the use of checkpoint inhibitors in new tumor types and new lines of treatment SHANGHAI, January 10, 2022 /PRNewswire/ -- On January 10, 2022 Beijing time, Junshi Biosciences (1877.
-
Ascletis Announces Submission of U.S. Clinical Trial Application for Fully Self-developed Oral PD-L1 Small Molecule Inhibitor ASC61 for the Treatment of Advanced Solid Tumors
Time of Update: 2022-01-25
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
(SEHK: 1672) today announced that the company has submitted a fully self-developed oral PD-L1 small molecule inhibitor ASC61 to the United States Clinical Trial Application (IND) for the treatment of advanced solid tumors .
-
Tsinghua University's 2022 Amgen Scholars Program Domestic Recruitment Plan Now Fully Launched
Time of Update: 2022-01-25
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
Tsinghua University will strive for excellence to create a more exciting summer scientific research practice, and leverage its complementary advantages with the Amgen Foundation to jointly promote the cultivation of innovative talents in the global medical science and technology field .
-
The State Food and Drug Administration has conditionally approved the marketing of icariin soft capsules for the treatment of hepatocellular carcinoma
Time of Update: 2022-01-25
The State Food and Drug Administration requires the holder of the marketing authorization of this variety to continue to complete the relevant post-marketing research work in accordance with the attached conditions and requirements .
